Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element

R Keul, M Roth, E Papakonstantinou, M Nauck, A P Perruchoud, L H Block

Abstract
Background – Broncho-Vaxom (OM-85 BV) increases the resistance of the respiratory tract to bacterial infections by modulating host immune responses. The compound increases serum IgG levels but decreases IgE levels in patients suffering from chronic bronchitis or chronic obstructive pulmonary disease. It increases concentrations of γ interferon (IFN-γ), IgA, and interleukin (IL)-2 in bronchoalveolar lavage fluid of patients with bronchitis. Treatment with OM-85 BV increases the number of T helper and natural killer cells. In this study the effects of OM-85 BV on transcription of cytokines is investigated in human lung fibroblasts.

Methods – Transcription and synthesis of IL-6 and IL-8 were assessed in cultured primary human lung fibroblasts using standard methods of Northern blot analysis for the level of mRNAs and enzyme linked immunosorbent assay for proteins.

Results – Broncho-Vaxom (OM-85 BV) at different concentrations induced transcription of IL-6 and IL-8. The effect of the drug on transcription of IL-6 and IL-8 genes correlated with secretion of the proteins into cell supernatants. OM-85 BV-dependent expression of the interleukin genes involved C-Fos/serum responsive element (C-Fos/SRE).

Conclusions – The data suggest that the various immunomodulatory activities of OM-85 BV that have been described in clinical studies may be explained by its ability to induce expression of IL-6 and IL-8.

(Keywords: immunomodulators, gene regulation, interleukin, lung fibroblasts.)

Broncho-Vaxom (OM-85 BV; OM Laboratories, Geneva, Switzerland), a lyophilised extract of eight species of bacteria which are frequently associated with inflammation of the respiratory tract, has been shown to modulate cellular immune mechanisms leading to increased resistance against bacterial infections. Oral administration of OM-85 BV induces the production of antibodies against the various components of the immunomodulator. OM-85 BV increases IgG levels but decreases IgE levels in patients with chronic bronchitis or chronic obstructive lung disease. Furthermore, treatment with OM-85 leads to increased concentrations of γ interferon (IFN-γ), IgA, and interleukin (IL)-2 in bronchoalveolar lavage (BAL) fluid of patients suffering from bronchitis. Long term administration of the drug increases the number of T helper and natural killer cells but decreases the number of T suppressor cells.

In vitro studies have shown that OM-85 BV induces the secretion of type E prostaglandins, tumour necrosis factor (TNF), and nitric oxide in isolated macrophages. The compound also stimulates the adhesion of human polymorphonuclear leucocytes to endothelial cells. These effects suggest a pharmacological potency of the drug at various levels of the immune system; however, its exact mode of action remains unclear.

A number of activities of IL-6 and IL-8 suggest that these factors have a significant role in mediating inflammatory and immune responses. IL-6 displays various proinflammatory effects that are potentially relevant to inflammation of the airways, including its ability to stimulate proliferation of thymocytes and T cells, to stimulate cytotoxic T lymphocyte differentiation, to upregulate IL-4 dependent IgE production, and to mediate the terminal differentiation and immunoglobulin production of B cells. In contrast, IL-6 has also been shown to diminish tissue inflammation in animal models of hypersensitivity pneumonitis, oxygen toxicity, and endotoxin-induced lung injury, and to inhibit macrophage production of IL-1. The proinflammatory effects of IL-8 are reflected by its ability to modulate the expression of various adhesion molecules in bronchial epithelial cells and lung macrophages. IL-8 also augments production of protease by neutrophils, generation of oxygen radicals, and activity of 5-lipoxygenase in polymorphonuclear leucocytes.

Since IL-6 and IL-8 may be of importance in the inflammatory mechanisms associated with infection and immunity, we have characterised the effects of OM-85 BV on the expression of IL-6 and IL-8 in human lung fibroblasts. This cell is known to be involved in the immune response initiated by infection or injury of the lung. We have investigated the effect of Broncho-Vaxom on the transcription, translation, and secretion of IL-6 and IL-8 in cultivated primary human lung fibroblasts.

Methods
CULTURE OF LUNG FIBROBLASTS
Five primary cell lines of fibroblasts were established from biopsy samples of human lung
Induction of IL-6 and IL-8 expression by Broncho-Vaxom

Figure 1  Kinetics of OM-85 BV-induced (10 μg/ml) transcription of IL-6 and IL-8 genes in human lung fibroblasts. Arbitrary units of mRNA were calculated by computerised image analysis of Northern blots in relation to the constitutive HLA-β gene. Each curve displays a representative analysis performed in one of the five primary cell lines of human lung fibroblasts; similar results were obtained with the other four cell lines.

tissue as described previously.  

Cells were cultivated in minimal essential medium supplemented with 10% fetal calf serum (FCS), 8 mM l-glutamine, and 1% vitamin mix to an 80% subconfluent monolayer. Subconfluent cultures of the cells were kept in low serum medium (0.5% FCS) for two days before stimulation with OM-85 BV (0.1–100 μg/ml) for various time periods (0, 0.5, 1, 2, 4, 6, 8, and 12 hours). All experiments were performed using cell lines in passages 1–4.

Figure 2: Dose dependence of OM-85 BV-induced transcription of IL-6 and IL-8 genes in human lung fibroblasts. The data represent the relative amounts of mRNA for the two interleukins assessed at the time points of maximal transcription (IL-6 at one hour; IL-8 at six hours). Each curve shows one representative analysis done in one primary cell line of human lung fibroblasts; similar results were obtained with the other four cell lines.

TRANSLATION AND SECRETION OF IL-6 AND IL-8

OM-85 BV-induced de novo synthesis of IL-6 and IL-8 proteins was tested in human fibroblasts. Quiescent subconfluent cultures were incubated for 12 hours in the presence of various concentrations of OM-85 BV (0.1 to 100 μg/ml). The cells were then scraped with a rubber policeman and sonicated on ice for 10 seconds (twice). The homogenate was centrifuged (five minutes, 10 000g, 4°C) and the amount of the two interleukins was determined.

Figure 3: Northern blot analysis of the modulatory effects of various inhibitors of transcription factors on OM-85 BV-induced transcription of IL-6 (at one hour), IL-8 (at six hours), TNF-α (at 12 hours), and c-fos (at 30 minutes) in human lung fibroblasts. Lane 1, unstimulated control fibroblasts; lane 2, OM-85 BV (10 μg/ml); lane 3, OM-85 BV + DMSO (2%); lane 4; OM-85 BV + polymyxin B (10 μM). Similar results were obtained with the remaining four cell lines.
Endotoxin assay

Contamination of OM-85 BV with lipopolysaccharides was excluded by means of a Limulus polyphemus lysate assay (EIA, Amer- 

sham, UK).

Results

Possible effects of OM-85 BV on the tran-

scription of various genes encoding interleukins 

(IL-1α/β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, 

IL-8, IL-10), colony stimulating factors (GM-

CSF, M-CSF, G-CSF), and tumour necrosis factor (TNF-α) were assessed in human lung 

fibroblasts. OM-85 BV specifically induced the 

transcription of two (IL-6, IL-8) of the 10 

cytokines investigated and the transcription of 

TNF-α. The transcription of IL-6 started 30 

minutes after the addition of the drug, reached 

a plateau between 1–2 hours (15 x), and 

declined thereafter (fig 1), while the transcrip-

tion of IL-8 started to increase two hours after 

the cells were stimulated with OM-85 BV and 

peaked at 4–6 hours (9 x). Only a slight in-

crease of the mRNA signal for TNF-α (1·5 x) 

was observed 12 hours after stimulation with 

OM-85 BV (fig 1).

The induction of the two interleukins was 

dose dependent (fig 2) with EC50 values of 

OM-85 BV in the range which can be obtained 

under therapeutic conditions. For all the 

following experiments an effective dose of 10 μg 

OM-85 BV/ml was used.

The ability of OM-85 BV to induce tran-

scription of the genes coding for the transcrip-

tion factors C-Fos and C-Jun was investigated. While the drug induced transcrip-

tion of the c-fos gene (fig 3), it failed to induce transcription of the c-jun gene.

Since activation of C-Fos requires the action 

of PKC,35 we further delineated the mode of 

action of OM-85 BV on gene activation by 

incubating cells with polymyxin B (10 μg/ml). In 

the presence of this inhibitor of PKC the 

OM-85 BV-induced transcription of c-fos, as 

well as the transcription of the two cytokine 

genes and of the gene coding for TNF-α, was 

abrogated (fig 3). In addition, OM-85 BV-

induced transcription of activated genes stud-

ied was abolished in the presence of actino-

mycin D (5 mg/ml) which suggests that the 

compound stimulates the de novo transcription of the respective genes (data not shown).

To evaluate the role of C-Fos/SRE on OM-

85 BV-induced transcription of c-fos and the 

two interleukin genes we tested the effect of 

DMSO (2%) which inhibits C-Fos/SRE.34 In 

the presence of DMSO the OM-85 BV-de-

pendent transcription of c-fos was completely 

blocked (fig 3). Similarly, the transcription of 

IL-6, IL-8, or TNF-α stimulated by OM-85 

BV was abolished in the presence of DMSO. 

DMSO alone did not affect the basal tran-

scription of the genes investigated.

OM-85 BV induced an increase of both the 

intracellular expression of IL-6 and IL-8 pro-

teins (fig 4A) and their secretion. Maximal 

tsecretion of both cytokines was observed 12 

hours after the addition of OM-85 BV to the 

culture medium (fig 4B). The OM-85 BV-

in the supernatant by enzyme linked im-

munosorbert assay (EIA).33

To determine secretion of interleukins 100 μl 
samples of culture medium were collected at 

0, 4, 8, and 12 hours and the amounts of 

proteins were assessed by EIA. All experiments 

were performed in triplicate with each cell line.

Transcription factors

Dimethyl sulphoxide (DMSO) 2% was used 

to determine the role of the C-Fos/SRE in OM-

85 BV-induced gene activation.34 Following 

incubation of the cells for various times, RNA 

was extracted for Northern blot analysis or 

cells were continued in culture to determine 

secretion of IL-6 and IL-8.

To investigate the involvement of protein 

kinase C (PKC) in OM-85 BV-dependent ac-

tivation of C-Fos34 35 subconfluent cultures 

of cells were incubated with the PKC inhibitor 

polymyxin B (10 μg/ml) for 30 minutes before 

stimulation with the OM-85 BV.
Induction of IL-6 and IL-8 expression by Broncho-Vaxom

Induction of IL-6 and IL-8 secretion by Broncho-Vaxom (OM-85 BV) involves the action of lipopolysaccharide. Lipopolysaccharide could be responsible for the effects on gene activation, cells were incubated with various concentrations of lipopolysaccharide that were equivalent to the lipopolysaccharide content determined in OM-85 BV. While lipopolysaccharide at concentrations of 1–10 ng/ml was found to induce transcription of cytokines, the amount of lipopolysaccharide contaminating OM-85 BV was <1 pg/mg. These concentrations were ineffective in inducing gene transcription (n = 3; data not shown). This clearly excludes unwarranted effects of the drug due to contamination with lipopolysaccharide.

**Discussion**

This present study shows that OM-85 BV is capable of modulating the immune response by specifically inducing the expression of IL-6 and IL-8 genes in human lung fibroblasts. The mechanism of transcription achieved by OM-85 BV involves the action of PKC, C-Fos and C-Fos/SRE. Considering the various autocrine and paracrine effects of IL-6 and IL-8, our observation may explain some of the immunopharmacological effects induced by OM-85 BV. The fact that lipopolysaccharide was not detectable in the preparations of OM-85 BV used excluded unwarranted effects of lipopolysaccharide.

IL-6 can be synthesised and released by a variety of cells including T and B lymphocytes, monocyte/macrophages, endothelial cells, and fibroblasts. It is induced by a number of cytokines such as IL-1, platelet-derived growth factor and TNF, viruses, and endotoxin via transcriptional and post-transcriptional mechanisms. In addition to its proinflammatory properties, IL-6 also displays some anti-inflammatory activities such as inhibition of macrophage proliferation, reduction of monocyte cytotoxicity, and inhibition of airway reactivity to methacholine. Furthermore, IL-6 activates the ability of B and T cells to combat infection and tissue damage by modulating synthesis of specific antibodies, predominantly of the IgA and IgG class. The latter effect could well account for the ability of OM-85 BV to increase levels of IgA and IgG in patients suffering from various inflammatory diseases of the lung. It may also explain the increased levels of IFN-γ and TNF-α in BAL fluid obtained from patients with chronic bronchitis after treatment with OM-85 BV.

It has recently been shown that IL-8 mediates accumulation and activation of polymorphonuclear leucocytes to endothelial cells after exposure to various inflammatory stimuli. Expression of IL-8 on lung fibroblasts may augment adherence of immunocompetent cells during phagocytic challenge by local modulation of the extracellular matrix and support trafficking of macrophages between alveolar and interstitial compartments during inflammation. Enhanced chemotactic activity as well as increased activity of the oxidative metabolism and intracellular killing of bacteria due to increased expression of IL-8 is paralleled by increased resistance to bacterial infections following treatment with OM-85 BV.

We have shown previously that OM-85 BV increases the concentration of intracellular free calcium via activation of phosphatidylinositol turnover. Induction of phosphatidylinositol turnover is usually paralleled by the activation of PKC. We have shown that inhibition of PKC, known to be essential for the action of C-Fos, abolished OM-85 BV-induced gene transcription. This is consistent with data obtained in the presence of DMSO, known to suppress activation of C-Fos/SRE. C-Fos/SRE binding sites have been identified in the promoter regions of the c-fos gene, the IL-6 and the IL-8 genes. Taken together, our data provide evidence that the signalling cascade, stimulated by OM-85 BV, involves the action of PKC and C-Fos/SRE resulting in expression of the interleukins IL-6 and IL-8 which both have potential anti-inflammatory organ protective properties.

This project was financed by Alfred-Krupp-Stiftung, Essen, Federal Republic of Germany, and OM Laboratorietes, CH-8102 Geneva, Switzerland.


Denis M. Interleukin-6 in mouse hypersensitivity pneumonitis: changes in lung free cells following depletion of murine IL-6 on direct administration of IL-6. *Leuk Lymph* 1992;52:197-201.


Standford TJ, Kunkel SL, Kasahara K, Milaj MJ, Rolfe MW, Strietter RM. Interleukin-8 gene expression from
Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element.

R. Keul, M. Roth, E. Papakonstantinou, M. Nauck, A. P. Perruchoud and L. H. Block

Thorax 1996 51: 150-154
doi: 10.1136/thx.51.2.150

Updated information and services can be found at:
http://thorax.bmj.com/content/51/2/150

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/